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Abstract
Background: Despite advances in the understanding of diabetic retinopathy, the nature and time
course of molecular changes in the retina with diabetes are incompletely described. This study
characterized the functional and molecular phenotype of the retina with increasing durations of
diabetes.
Results: Using the streptozotocin-induced rat model of diabetes, levels of retinal permeability,
caspase activity, and gene expression were examined after 1 and 3 months of diabetes. Gene
expression changes were identified by whole genome microarray and confirmed by qPCR in the
same set of animals as used in the microarray analyses and subsequently validated in independent
sets of animals. Increased levels of vascular permeability and caspase-3 activity were observed at 3
months of diabetes, but not 1 month. Significantly more and larger magnitude gene expression
changes were observed after 3 months than after 1 month of diabetes. Quantitative PCR validation
of selected genes related to inflammation, microvasculature and neuronal function confirmed gene
expression changes in multiple independent sets of animals.
Conclusion:  These changes in permeability, apoptosis, and gene expression provide further
evidence of progressive retinal malfunction with increasing duration of diabetes. The specific gene
expression changes confirmed in multiple sets of animals indicate that pro-inflammatory, anti-
vascular barrier, and neurodegenerative changes occur in tandem with functional increases in
apoptosis and vascular permeability. These responses are shared with the clinically documented
inflammatory response in diabetic retinopathy suggesting that this model may be used to test anti-
inflammatory therapeutics.
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Background
Diabetic retinopathy (DR) is one of the most debilitating
diabetic complications. DR is best prevented by intensive
glycemic control as demonstrated by the Diabetes Control
and Complications Trial (DCCT) study [1]. Established
treatments of DR are limited to panretinal laser photoco-
agulation therapy and control of hypertension [2].
However, the ability to achieve intensive glycemic control
through insulin is limited by hypoglycemia, and given
that islet cell transplants are not widely available, pharma-
cotherapies for prevention and treatment of DR are
needed. The PKC inhibitor ruboxistaurin has shown
promise as a therapeutic agent [3], but this compound did
not receive FDA approval. Therefore, continued develop-
ment is needed for DR therapies.
The etiology and pathological processes of DR remain
imperfectly understood with the major pathophysiolgical
hypotheses being microvascular proliferation and/or per-
meability [4], advanced glycation endproducts (AGEs)
[5], PKC activation [6], oxidative stress [7], inflammation
[8], loss of insulin signaling, and neurodegeneration [9].
Previously, we proposed that these different processes are
not mutually exclusive, but rather could represent differ-
ent components of a feed-forward cycle of nutrient over-
load leading to chronic inflammation,
neurodegeneration, and compromised blood-retinal bar-
rier function [9].
Previous work has provided important insights into the
genomic and proteomic changes associated with DR [10-
13]. This study sought to tie changes in retinal gene
expression to functional changes in the retina as measured
through vascular permeability and apoptosis. Clinical DR
is a progressive disease; therefore the rodent model
should also demonstrate progressive dysfunction with
increasing duration of diabetes. This study accomplished
two goals in examining aspects of the retinal response to
diabetes: first, to demonstrate functional changes in reti-
nal permeability and caspase-3 activity (as a surrogate for
apoptosis) after 1 and 3 months of experimental diabetes,
and second, to identify and confirm retinal gene expres-
sion alterations at 1 and 3 months of diabetes.
Results
At harvest, as predicted by earlier assessments, diabetic
rats were hyperglycemic and underweight in comparison
to control rats (Table 1). These data and the methods
described are representative of experiments performed by
the Penn State JDRF Animal Models Core since 2003 [14].
Vascular permeability and apoptosis
Retinal vascular permeability, as measured by FITC-BSA
incorporation into nonvascular retinal tissue, was
unchanged at 1 month of diabetes but was significantly
increased (52%, p < 0.05) after 3 months of diabetes
(Table 2). Similarly, caspase-3 activity was unchanged
after 1 month of diabetes but was increased significantly
after 3 months of diabetes (24%, p < 0.05) (Table 2).
Microarray analysis
22,578 probes had detectable signal at both the 1 and 3
month time points. Expression values were generally con-
sistent across rats and arrays in the study. Diabetes-associ-
ated changes were of a higher number and magnitude at 3
Table 1: Animal Data. Mean weight and blood glucose at the time of sacrifice for the different sets of animals and their respective 
analyses. Mean ± S.E.M.
N Weight (g) Blood Glucose (mg/dL) Analyses
Set 1 1 Month Control 5 411 ± 7 87 ± 3 Microarray & qPCR
STZ 6 317 ± 16 303 ± 8
3 Month Control 6 617 ± 11 93 ± 4 Microarray & qPCR
STZ 6 303 ± 8 370 ± 21
Set 2 1 Month Control 6 391 ± 9 114 ± 12 qPCR
STZ 6 264 ± 16 321 ± 16
3 Month Control 6 587 ± 18 106 ± 3 qPCR
STZ 6 319 ± 16 335 ± 10
Set 3 3 Month Control 6 574 ± 8 91 ± 13 qPCR
STZ 8 364 ± 17 377 ± 33
Set 4 1 Month Control 8 379 ± 11 90 ± 3 Caspase
STZ 8 277 ± 9 426 ± 23
3 Month Control 8 545 ± 22 78 ± 2 Caspase
STZ 7 341 ± 27 475 ± 24
Set 5 1 Month Control 9 379 ± 11 133 ± 12 Permeability
STZ 11 296 ± 12 486 ± 21
3 Month Control 8 592 ± 10 116 ± 4 Permeability
STZ 7 325 ± 23 430 ± 37BMC Medical Genomics 2008, 1:26 http://www.biomedcentral.com/1755-8794/1/26
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months as compared to 1 month post-STZ injection (Fig-
ure 1). The mean fold changes were 1.3 ± 0.6 fold for 1-
month changes (124 genes) and 1.7 ± 0.4 fold for the 3
month changes (2310 genes). The full set of gene expres-
sion data has been deposited in the NIH/NLM Gene
Expression Omnibus (GEO accession # GSE11733) [15].
To determine processes or functional groupings which are
altered with diabetes, ontological analysis was performed
using Gene Ontology (GO) categories [16]. Ontology
results identified a number of physiological processes and
molecular functions altered in the diabetic animals (Fig-
ure 2). Of special note was the significant induction of the
gene ontologies for the physiological processes of
cytokine production/immune response at 3 months of
diabetes. Also regulated were ontologies related to
cytoskeleton/crystallin proteins and GABA receptor activ-
ity.
Based on statistical analysis of microarray data and avail-
able gene information, including previous reports, 32
genes were chosen for qPCR confirmation and validation
(Table 3). These 32 genes represent both genes not previ-
ously associated with DR as well as those described with
DR or other retinal pathologies, including clinical reports
[13]. These genes were placed post hoc in three categories
to aid in organization and presentation. These groups are
not intended to be definitive or exclusionary nor do they
preclude genes from having multiple functions across the
different categories and these groupings do not represent
canonical gene ontology classes. Nine genes were placed
Table 2: Caspase and Permeability Data: Retinal vascular permeability and apoptosis was measured at 1 and 3 month time points.
N Percent Mean Control
Permeability 1 Month Control 9 100 ± 8%
STZ 11 98 ± 8%
3 Month Control 8 100 ± 3%
STZ 71 5 2  ±  8 % *
Caspase-3 Activity 1 Month Control 8 100 ± 9%
STZ 8 100 ± 10%
3 Month Control 8 100 ± 17%
STZ 71 2 5  ±  1 6 % *
Values are expressed as a percentage of the control condition at that time point ± S.E.M. *p < 0.05, t-test.
Microarray analysis Figure 1
Microarray analysis. A. Differences in RNA expression 1 or 3 months after STZ induced diabetes were analyzed by Code-
link whole genome microarray. After filtering for genes detected as present, differential expression was determined by 
ANOVA p < 0.01 and a fold change of 1.2 fold or greater. For differentially expressed genes values for each of the five animals 
in control and STZ treated groups are given in log scale normalized as described in the Methods. Lines are colored according 
to their relative normalized expression level. Far more changes and larger magnitude changes were detected after 3 months of 
STZ-induced diabetes as opposed to 1 month. B. Set analysis of the changes at 1 month and 3 months of STZ-induced diabetes 
demonstrates that the vast majority of 3 month changes are not observed at 1 month of STZ-induced diabetes.
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in the neuronal function group, 8 in the microvascular,
and 15 in the inflammatory-related group. The 32 genes
examined by qPCR are only a subset of the changes
observed in the microarray analysis since qPCR confirma-
tion of microarray changes (2401 genes) was not logisti-
cally feasible. Other genes/processes which were
examined further are described in other reports [17,18].
qPCR confirmation and validation
Quantitative PCR analysis occurred in several steps. First,
genes were confirmed for expression changes in the same
set (Set 1, Table 1) of animals as used in the microarray
analysis. Second, gene expression changes were validated
in a second, independent set of animals (Set 2). Samples
from the 3 month time point of Set 1 were exhausted
before completion of the study and therefore another set
(Set 3) of independent animals was generated for the 3
month time point. Genes were considered to be con-
firmed if the gene expression change was statistically sig-
nificant at the appropriate time point in all of the animal
sets tested.
Microvascular-related genes demonstrated highly repro-
ducible changes across three independent sets of rats with
5 genes significantly altered at the 3 month time point
(EDN2, EDNRB, ICAM1, MCT1, NPPA). For a complete
listing of full gene names and synonyms see Table 3.
VEGFA reproducibly decreased at 1 month (Figure 3).
Two microvascular-related genes (NPR3, VCAM1) did not
qPCR confirmation of microvascular-related gene changes  across multiple sets of animals Figure 3
qPCR confirmation of microvascular-related gene 
changes across multiple sets of animals. qPCR data is 
normalized to give mean control values of 1 and the different 
sets are color coded per the inset. T-test, *p < 0.05, **p < 
0.01, ^p < 0.001. EDN2, endothelin 2; EDNRB, endothelin 
receptor type B; ICAM1, intercellular adhesion molecule 1; 
MCT1, monocarboxylate transporter 1; NPPA, natriuretic 
peptide precursor type A; VEGFA, vascular endothelial 
growth factor A.
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Ontological analysis of 1 month and 3 month micro-
array changes. Gene Ontology (GO) categories were que-
ried for statistically significant overabundances of specific 
physiological processes or molecular functions. Statistical 
analysis was performed by taking the number of members of 
each process or function on the array and determining the 
number of changes that would be in that process by random 
chance. Processes or functions with a p value < 0.01 are 
given with GO accession #, function or process name and 
number of genes in that function or process. No statistically 
altered physiological processes were found for 1 month 
changes.
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reach a statistically significant level of change in all sets of
rats [See Additional file 1]. Of the 15 inflammatory genes
tested, 12 genes (C1-INH, CCR5, CD44, CHI3L1, HSPB1,
JAK3, LGALS3, LGALS3BP, LAMA5, PEDF, STAT3, TIMP1)
were reproducibly upregulated at 3 months (Figures 4
&5). CCL2 (MCP-1) was increased at both 1 and 3 month
time points (Figure 5). Of particular note were common-
alities with a recent seminal report of vitreous protein lev-
els in proliferative DR patients (Figure 5) [13]. The
magnitude of induction in the inflammatory genes was
much larger than other groups with inductions as high as
80 fold. Two inflammatory transcripts were not con-
firmed as gene expression changes [IL1β, IL6 [See Addi-
tional file 2]. All 7 confirmed neuronal function-related
genes (DCAMKL1, GAT3, GRIN2A, KCNE2, PCGF1,
PEPT2, ZNF219) revealed reproducible decreases at 3
months of STZ-induced diabetes (Figure 6). Two genes
(CHRNA4, FEZ2) did not change in a statistically signifi-
cant manner in all sets of rats [See Additional file 3]. In
general, expression ratios were similar between microar-
ray and qPCR measurements. An exact technical compar-
ison is not possible as, in most cases, different animals
(Set 1vs Set 2 or 3) and different numbers (N) of animals
used in the microarray and qPCR analyses.
To visualize the entire pattern of gene expression meas-
ured by qPCR in the different sets of animals the qPCR
gene expression data was used to generate a Principle
Components Analysis (PCA) plot (Figure 7). This allows
for visualization of the relationship between sets of ani-
mals at different time points and treatments. The first
component provides separation between control and dia-
betic sets and accounts for 75.6% of the study variance
providing further evidence of the reproducibility of the
diabetic effect. Furthermore, the 1 month animal sets rep-
resent a midpoint between control and 3 month diabetic
animals. This demonstrates that while most of these genes
are not statistically altered at 1 month, there is a gene
expression pattern developing prior to onset of significant
increases in vascular permeability and apoptosis. The sec-
ond component accounted for a much smaller percentage
of the study variance (8.5%) and represents the variability
between the independent sets of animals. Therefore, these
gene expression changes are a robust effect compared to
inter-experiment variability.
Discussion
The purposes of this study were to examine retinal perme-
ability and apoptosis at 1 and 3 months of diabetes and to
identify accompanying retinal mRNA expression changes.
The time points of this study were chosen as models of the
chronic progressive nature of complications such as DR
and are consistent with previous studies [14,19]. The find-
ings of the study demonstrate that changes in retinal
expression of inflammatory, microvascular, and neuronal
transcripts occur in concert with functional changes in ret-
inal permeability and apoptosis.
The increased vascular permeability reported here (52%)
closely replicates our previous findings of increased vascu-
lar permeability (62%) at 3 months of diabetes [19]. Sim-
ilarly, we confirmed our previous finding of increased
caspase-3 activity at 3 months of diabetes [14]. We both
confirm that these changes are evident at 3 months of dia-
betes and report that there are no changes in vascular per-
meability and caspase-3 activity at 1 month by these
methods. Lack of significant change in permeability and
apoptosis with the assays used at 1 month of diabetes pro-
qPCR confirmation of inflammation-related gene changes  across multiple sets of animals Figure 4
qPCR confirmation of inflammation-related gene 
changes across multiple sets of animals. qPCR data is 
normalized to give mean control values of 1 and the different 
sets are color coded per the inset. T-test, *p < 0.05, **p < 
0.01, ^p < 0.001. CCR5, chemokine (C-C motif) receptor 5; 
CD44, cell surface glycoprotein CD44; HSPB1, heat shock 27 
kDa protein 1; JAK3, janus kinase 3; LAMA5, laminin, alpha 5; 
STAT3, signal transducer and activator of transcription 3; 
TIMP1, tissue inhibitor of metalloproteinase 1.
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vides the opportunity to assess those gene expression
changes which occur before and/or concomitantly with
functional alterations.
Thirty two genes significantly altered in the microarray
analysis were subjected to qPCR confirmation. After qPCR
confirmation of 26 of these genes in multiple sets of ani-
mals, these genes were placed in the microvascular, neu-
ronal function and inflammatory gene sets because they
represent central hypotheses of retinal cellular alterations
with diabetes. While the interactions of the microvascular
and neuronal cells along with inflammatory activation are
not fully understood, the various retinal cells clearly func-
tion in a coordinated fashion with integrated metabolism
and cell – cell contacts. We have previously postulated a
"feed-forward" interaction concept in which defects in
vascular, neural and inflammatory responses to diabetes
perpetuate the neurovascular degeneration [9]. These
genes were tested across replicate sets of rats to determine
those which were reproducibly altered. A major finding of
this work is the reproducibility of these changes across
independent experiments. Many more differentially regu-
lated genes from the microarray analysis remain to be
confirmed and expanded upon [as described elsewhere
Table 3: Gene names, aliases, and qPCR assay numbers.
Gene Grouping Gene Symbol Assay-on-Demand 
Catalogue #
Gene Name Aliases
Microvascular EDN2 Rn00561135_m1 Endothelin 2 ET2
EDNRB Rn00569139_m1 Endothelin receptor B ETRB, ETB
ICAM1 Rn00564227_m1 Intercellular adhesion molecule 1 CD54
MCT1 Rn00562332_m1 Monocarboxylate transporter 1 Slc16a1
NPPA Rn00561661_m1 Natriuretic peptide precursor A ANP
NPR3 Rn00563495_m1 Natriuretic peptide receptor 3 NPR-C, ANP-CR
VCAM1 Rn00563627_m1 Vascular cell adhesion molecule 1
VEGFA Rn00582935_m1 Vascular endothelial growth factor 
A
VEGF
Inflammatory C1-INH Rn01485600_m1 Complement 1-inhibitor Serping 1, C1NH, C1l
CCL2 Rn00580555_m1 Chemokine (C-C motif) ligand 2 MCP1, GDCF2, MCAF, SCYA2, 
SMCCF
CCR5 Rn00588629_m1 Chemokine, CC Motif, Receptor 5 CCCKR5, CMKBR5, CKR5
CD44 Rn00563924_m1 Cd44 antigen CDW44, Pgp1
CHI3L1 Rn01490608_m1 Chitinase 3-Like 1 GP39, YKL40
HSPB1 Rn00583001_g1 Heat shock 27 kDa protein 1 HMN2B, HSP27, HSP28, HSP25
JAK3 Rn00563431_m1 Janus Kinase 3 JAKL
IL-1β Rn00580432_m1 Interleukin 1 beta IL-1
IL-6 Rn00561420_m1 Interleukin 6 BSF2, HGF, HSF, IFNB2, IL-6
LAMA5 Rn01415966_g1 Laminin, alpha 5
LGALS3 Rn00582910_m1 Lectin, galactoside-binding, soluble, 
3
CBP35, GAL3, GALBP, MAC2
LGALS3BP Rn00478303_m1 lectin, galactoside-binding, soluble, 
3, binding protein
MAC2BP, Serum Protein 90K
PEDF Rn00709999_m1 Pigment epithelium-derived growth 
factor
SERPINF1
STAT3 Rn00680715_m1 Signal transducer and activator of 
transcription 3
APRF
TIMP1 Rn00587558_m1 Tissue inhibitor of 
metalloproteinase 1
EPA
Neuronal Function CHRNA4 Rn00577436_m1 Cholinergic receptor, nicotinic, 
alpha
BFNC, EBN, EBN1, NACRA4
DCAMKL1 Rn00584294_m1 Doublecortin-like kinase 1 Dckl1, Cpg16
FEZ2 Rn01468629_m1 Fasciculation and elongation zeta 2 Zygin II
GRIN2A Rn00561341_m1 Glutamate receptor, ionotropic, 
NMDA 2A
NMDAR2A, NR2A
KCNE2 Rn02133036_s1 Isk-related voltage-gated K+ channel 
2
LQT5, LQT6, MGC138292, 
MIRP1
PCGF1 Rn01425394_g1 Polycomb group ring finger 1 Nspc1
PEPT2 Rn00581522_m1 Proton-dependent high affinity 
oligopeptide transporter
Slc15a2
GAT3 Rn00577664_m1 GABA transporter 3 Slc6a11
ZNF219 Rn01414563_g1 Zinc finger protein 219 ZFP219BMC Medical Genomics 2008, 1:26 http://www.biomedcentral.com/1755-8794/1/26
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[17,18]]. As mRNA levels do not always correspond to
protein expression levels, future studies will be needed to
address changes in protein levels and precise cellular
localization of these changes.
Microvascular
Microvascular dysfunction is a hallmark of DR, with
numerous reports of diabetes-induced changes in humans
as well as in animal models. Several reproducibly altered
microvascular transcripts were confirmed in this study
(Figure 3). ICAM1 (intercellular adhesion molecule 1) is
commonly associated with retinal disease states, as adhe-
sion molecules are produced by vascular endothelial cells
are induced during the proliferative stages of DR [20].
ICAM1 suppression decreases leukostasis and vascular
leakage in retinas of STZ-diabetic rats [21] and ICAM1
deficient STZ treated mice demonstrate reduced leukocyte
adhesion and vascular permeability as compared to wild-
type [22].
While the EDN1 (endothelin 1) alterations have been
well described in DR, induction of EDN2 (endothelin 2),
a potent vasoconstrictor, and the endothelin receptor
EDNRB (endothelin receptor B) have been described after
6 months of diabetes and light injury [23,24]. NPPA
(natriuretic peptide precursor type A; also known as atrial
natriuretic peptide, ANP) is an antigrowth factor in
endothelial cells that counteracts the angiogenic and per-
meability actions of VEGF. NPPA is also protective against
NMDA-induced retinal neurotoxicity [25]. Our findings
concur with a recent report of decreased NPPA mRNA and
protein levels at 3 months but not 1 month of STZ-diabe-
tes in rats [26].
Retinal mRNA levels of MCT1 (monocarboxylic acid
transporter 1), transporter of lactate and pyruvate between
astrocytes and neurons, were previously reported to be
unchanged in the rat retina at 10 weeks of STZ-induced
diabetes [27]. However, MCT1 mRNA levels were consist-
ently decreased at 3 months of diabetes in this study.
Induction of retinal VEGFA (vascular endothelial growth
factor) protein with diabetes is well known, but previous
studies of VEGF mRNA have produced conflicting results.
For example, retinal VEGF mRNA levels have been
reported to be unchanged at 3 months [28], increased at 6
months [29], and decreased at 6 months [12] duration of
STZ-induced diabetes in the rat. We demonstrate a con-
sistent decrease in VEGF mRNA expression in multiple
independent sets of animals. The lack of concordance
with previously described increases in VEGF protein sug-
gests a post-translational mechanism for VEGF protein
regulation. In total, these microvascular gene expression
differences indicate a synergistic increase in microvascular
dysfunction (ICAM1, EDN2, and EDNRB) and decrease in
a potential compensatory mechanism (NPPA).
Inflammation
Altered inflammatory equilibrium has the potential to
exacerbate or be induced by both the neurodegenerative
and microvascular dysfunctions typical of DR [9]. Clini-
cally, elevated vitreal levels of pro-inflammatory cytokines
have been described (e.g. [10,13]). Our findings confirm
the induction of many of these same factors in a rodent
model and provide evidence of a number of novel inflam-
mation-related changes (Figures 4 &5), some of which
have also been described in Müller cells after 6 months of
experimental diabetes [12]. The majority of the genes can
be described as pro-inflammatory (CCL2, CCR5, CD44,
CHI3L1, JAK3, STAT3, TIMP1, LAMA5, LGALS3, and
LGALS3BP) with some potentially anti-inflammatory
changes (PEDF, HSPB1, C1-INH).
Pro-inflammatory changes included chemokines, recep-
tors, and signaling molecules. All of these genes have mul-
tiple points of interaction with inflammatory and
chemotactic cascades which themselves are often associ-
ated with breakdown of vascular barrier properties and
neurodegeneration. Specifically, elevated CCL2 (chemok-
ine, CC motif, ligand 2), (also known as Scya2; Small
inducible Cytokine A2, and MCP-1; monocyte chemotac-
tic protein 1) has been reported in the vitreous of patients
with proliferative DR [30], with increased CCL2 correlat-
ing with increasing severity of proliferative DR [31]. The
high level of induction at 1 month (20.9 fold in set 1 and
5.4 fold in set 2) and even higher elevation at 3 months
(84.1 fold in set 2 and 13.0 fold in set 3) demonstrates for
the first time that CCL2 mRNA is increased in the retina of
STZ-diabetic rats and suggests a very strong pro-inflamma-
tory response that occurs within one month of diabetes
and progresses with time.
CCR5 (chemokine, CC motif, receptor 5) a RANTES
receptor facilitates leukocyte infiltration into the retina
[32] and could work synergistically with elevated levels of
RANTES present with diabetes [33]. CD44 is a widely
expressed glycoprotein that plays a direct role in leukocyte
trafficking to the retina [34]. The systemic plasma levels of
the primary ligand for CD44, hyaluronan, are increased in
diabetic patients [35]. In a manner similar to CCR5,
increased CD44 levels could work synergistically with ele-
vated levels of its ligand to recruit leukocytes.
JAK3 (janus kinase 3) expression requires cytokine signal-
ing and inhibition of JAK3 prevents STAT3 activation [36].
STAT3 (signal tranducer and activator of transcription 3)
has been localized to the inner nuclear layer and ganglion
cells [37]. TIMP-1 (tissue inhibitor of metallopeptidase1)
expression is regulated through STAT3 [38] and TIMP-1 isBMC Medical Genomics 2008, 1:26 http://www.biomedcentral.com/1755-8794/1/26
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induced in the epiretinal membranes of Type 1 and Type
2 diabetic patients [39].
CHI3L1 (chitinase 3-like 1) is an inflammatory marker
associated with acute and chronic inflammation, chemo-
taxis, and angiogenesis. CHI3L1 plasma levels in Type II
diabetes patients are positively correlated with insulin
resistance and endothelial dysfunction [40]. LGALS3 (lec-
tin, galactosidase-binding, soluble, 3), also known as
GAL3 (galectin 3), plays many roles in inflammatory
responses as an advanced glycation end-products (AGE)
receptor [41]. AGEs are elevated in diabetic tissues and
sera [42]. Removal of LGALS3 inhibits AGE-mediated ret-
inal ischemia and suggests an important role for LGALS3
in AGE-related pathophysiology [43]. LGALS3BP (lectin,
galactosidase-binding, soluble, 3, binding protein), is a
cell adhesion binding protein for LGALS3 and is elevated
in patients with DR [13]. There are no reported data
describing the role of LAMA5 (Laminin, alpha-5) retina,
however, laminin-LGALS3 interactions can promote leu-
kocyte adhesion [44].
The three potentially anti-inflammatory gene expression
changes confirmed (C1-INH, HSPB1, and PEDF) may rep-
qPCR confirmation of inflammation-related genes previously  reported in patients with DR Figure 5
qPCR confirmation of inflammation-related genes 
previously reported in patients with DR. qPCR data is 
normalized to give mean control values of 1 and the different 
sets are color coded per the inset. T-test, *p < 0.05, **p < 
0.01, ^p < 0.001. C1-INH, complement component 1 inhibi-
tor; CCL2, chemokine (C-C motif) ligand 2; ChI3L1, chitinase 
3-like 1; LGALS3, lectin, galactoside-binding, soluble, 3; 
LGALS3BP, lectin, galactoside-binding, soluble, 3, binding 
protein; PEDF, pigment epithelium-derived factor.
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qPCR confirmation and validation of neuronal function- related genes with consistent changes in multiple sets of ani- mals Figure 6
qPCR confirmation and validation of neuronal func-
tion-related genes with consistent changes in multi-
ple sets of animals. qPCR data is normalized to give mean 
control values of 1 and the different sets are color coded per 
the inset. T-test, *p < 0.05, **p < 0.01, ^p < 0.001. 
DCAMKL1, doublecortin-like kinase 1; KCNE2, potassium 
voltage-gated channel, Isk-related family, member 2; PCGF1, 
polycomb group ring finger 1; PEPT2, proton-dependent high 
affinity oligopeptide transporter; GAT3, Gamma-aminobu-
tyric transporter 3; ZNF 219, zinc finger protein 219.
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resent a compensatory response to aspects of the pro-
inflammatory response. C1-INH (complement compo-
nent 1 inhibitor), also known as Serping1 [serine (or
cysteine) peptidase inhibitor, clade G, member1], protein
expression is increased in DR patients and C1-INH blocks
the increased permeability caused by vitreal injection of
carbonic anhydrase [13]. HSPB1 (heat-shock 27-kD pro-
tein 1), also commonly known as Hsp27, inhibitis both
caspase-dependent and -independent apoptosis [45] and
is protective against oxidative stress breakdown of barrier
integrity [46].
The observation that PEDF (pigment epithelium-derived
factor) counteracts the effects of VEGF through antiang-
iogenic properties [47] has been challenged by recent
report of elevated levels of PEDF in patients with prolifer-
ative DR than controls [48]. In fact, increased vitreal levels
of PEDF have been described in other DR clinical reports
[13]. We also observe an induction of PEDF and more
studies will be needed to determine if PEDF induction is a
compensatory response to other inflammatory and ang-
iogenic changes or if it has a different purpose.
The majority of these inflammatory changes occur at 3
months of diabetes, the same time as the functional
changes. However, the marked induction of CCL2 occurs
before observed changes in permeability and apoptosis.
This may represent an initial event which leads to the cas-
cade of events eventually resulting in retinal dysfunction.
Examination of the entire pattern of gene expression (Fig-
ure 7) raises the possibility that small magnitude changes
could be working in concert to progressively cause later
retinal dysfunction.
Neuronal function
We have previously reviewed the neuronal components of
DR pathophysiology and the role of neurodegeneration in
vision loss [9]. The data presented in this study establish
transcriptional alterations in a set of genes related to neu-
ronal function, all suggestive of neurodegeneration.
DCAMKL1 (doublecortin-like kinase 1) is highly
expressed in the ganglion cell layer [49] and functions
with Doublecortin in microtubule stabilization. Further
studies will be needed to determine if a decrease in
DCAMKL1 could be associated with reductions or weak-
ening of synapses observed in diabetic rat retinas [17].
PEPT2 (proton-coupled peptide transporter, Slc15a2)
transports peptides across membranes in a low capacity/
high affinity manner and is expressed in the inner nuclear
layer Müller cells and in astrocytes of the retinal ganglion
layer [50]. GAT3 (GABA transporter 3, Slc6a11) is found
on both neuronal and glial cells in the retina [51]. The
possible role of decreased GABA uptake in retinal pathol-
ogy is unclear, but could induce electrophysiological
changes in the diabetic retina [52].
KCNE2 (isk-related voltage-gated K+ channel 2) colocal-
izes with KCNQ channel members to regulate channel
activity. While KCNE2 is uncharacterized functionally in
the retina, it is highly enriched in rods [53]. GRIN2A
(ionotropic glutamate receptor 2a, NMDAR2a) receptors
are poorly characterized in the retina, but could play a role
in the altered dark adaptation as neurotransmission is
increased in the dark [54].
PCGF1 (polycomb group ring finger 1), also known as
nervous system polycomb 1 (NSPc1), is a nervous system
transcription repressor regulated by PKC signaling [55].
ZNF219 (zinc finger protein 219, or Zfp219) is an unchar-
acterized transcriptional repressor [56] with highest
expression in the brain and nervous system.
Condition clustering using qPCR data Figure 7
Condition clustering using qPCR data. qPCR data from 
the set of 26 validated genes in the previous figures was clus-
tered by principle components analysis (PCA) to provide a 
visualization of the relationship between treatments and 
experiment sets. The 1st component, corresponding to the 
experimental treatment accounted for 75.6% of the variance, 
while the replicate set of animals were separated by the 2nd 
component, accounting for 8.5% of the variance. Of note is 
that the 1 and 3 month STZ groups separate from the con-
trol animals and from each other, suggesting that a pattern of 
altered expression is beginning at 1 month. A high degree of 
similarity was evident between all of the control groups. Set 
1 3 month data is not included because values for all genes 
could not be collected.
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While existing knowledge of these neuronal function-
related genes in the retina is limited, the collective
decreases observed indicate a compromised neuronal
phenotype. Current work suggests that neurodegenera-
tion in diabetic retinopathy includes a synaptic compo-
nent that may lead to reduced neuronal function and
signaling [17] further developing the concept of a com-
promised neuronal phenotype [9].
Lastly, to visualize the interactions between the different
genes confirmed by qPCR, the Ingenuity Pathway Analysis
(IPA) system was used to generate a network of gene inter-
actions. Twenty-two of the genes confirmed by qPCR,
along with increased caspase activity and decreased insu-
lin levels created a network of interactions [See Additional
file 4]. The additional genes and vascular permeability val-
ues were not able to be included in a rigorously generated
network. This does not preclude them from having roles
in the network. While these network analyses can only use
known interactions, these increases in expression or activ-
ity (red fills) and decreases in expression or levels (green
fills) could act synergistically, as we have previously pro-
posed [9]. Furthermore, when previously described roles
of these transcripts in functions and diseases (inflamma-
tion, diabetes, non-proliferative DR, and neuropathy) are
overlaid onto the network, a number of interactions are
obvious (orange highlights). As we have discussed above,
the combination of these changes could produce a neu-
rovascular inflammatory response.
Conclusion
Each of the genes described has potential roles in the
increased vascular permeability and apoptosis observed. A
critical finding of this study is that a number of inflamma-
tory genes (C1-INH, CCL2, LGALS3, LGALS3BP, and
PEDF) are induced in a manner similar to clinical reports
of patients with DR [13]. These inductions occur in tan-
dem with increases in vascular permeability and apoptosis
that are analogous to the clinically observed changes in
barrier properties and apoptosis. These findings suggest
that the STZ-rat could be used to model aspects of clinical
DR, especially inflammation. The STZ-rat model may pro-
vide a useful preclinical tool to investigate the specific
roles of these genes in diabetes-induced retinal patho-
physiology. This model may also serve as a preclinical
model for studies of potential therapeutics to assess their
efficacy in preventing or reversing deregulation of retinal
gene expression and pathophysiology with diabetes.
The individual genes identified and confirmed here are
points of interest for future studies focused on elucidating
the role of each gene product in normal retinal physiology
and DR. Together, the panel of genes altered with diabetes
provides further evidence to support the hypothesis of a
feed-forward cycle of chronic inflammation, neurodegen-
eration, and compromised blood-retinal barrier function
in the pathophysiological development of DR.
Methods
Animals
Experiments were performed following the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision
Research protocols. All rats were maintained by the Penn
State JDRF Animal Core in accordance with the Institu-
tional Animal Care and Use Committee guidelines under
specific pathogen-free conditions and monitored by quar-
terly sentinel testing. Sprague Dawley male rats (Charles
River Laboratories, Wilmington, MA) arrived at 100–125
grams. After one week and following an overnight fast,
diabetes was induced by intraperitoneal injection of 65
mg/kg streptozotocin (Sigma-Aldrich, St. Louis, MO) in
10 mM sodium citrate pH 4.5 vehicle. Control rats were
injected with an equal dose of vehicle only. Rats had free
access to food and water, and were on a 12 hour light/dark
cycle. Blood glucose level and body weight were measured
6 days post-STZ or vehicle injection, and biweekly
throughout the experiment. Only rats with blood glucose
levels >250 mg/dL at the time of the original test were
included in the diabetic groups (Table 1, Online Appen-
dix). No exogenous insulin was delivered. At the time of
retinal harvest, rats were given a lethal dose of pentobar-
bital, 100 mg/kg, (Ovation Pharmaceuticals Inc., Deer-
field, IL) by intraperitoneal injection. Retinas were excised
and quickly frozen in liquid nitrogen.
Vascular permeability
Blood-retinal barrier permeability was measured in rats
after 1 and 3 months after streptozotocin (STZ) treatment
using a FITC-BSA modification of the method described
by Xu et al. [57] using FITC-BSA. Under ketamine/xyla-
zine anesthesia (67/6.7 mg/kg body weight, i.m.), ani-
mals received femoral vein injection of 100 mg/kg body
weight of fluorescein isothiocyanate-bovine serum albu-
min (FITC-BSA) in sterile PBS (Sigma, St. Louis, MO).
After 2 hours, the animals were anesthetized again with
ketamine/xylazine. The abdominal cavity was opened and
1 ml blood was drawn from the inferior vena cava to
obtain the FITC-BSA concentration in plasma. Subse-
quently, the heart of the animal was perfused for 2 min
with citrate buffer (50 mM, pH 3.5, 37°C) containing 1%
paraformaldehyde (Fisher, Pittsburgh, PA). After per-
fusion, retinas were harvested from both eyes and dried in
a Savant Speed-Vac (Thermo Scientific, Waltham, MA).
The FITC-BSA was extracted by incubating each retina in
200  μl PBS with 1% Triton X-100 (Sigma) and 0.1%
sodium azide (Fisher) rocking at room temperature over-
night. The extract was transferred to a filter tube and cen-
trifuged at 5,000 × g for 3 hours. Plasma and retina extract
samples were assayed in triplicate of 50 μl/well in a 96-
well black/clear bottom plate (BD Biosciences, FranklinBMC Medical Genomics 2008, 1:26 http://www.biomedcentral.com/1755-8794/1/26
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Lakes, NJ) for fluorescence with a SpectraMax Gemini EM
fluorescent plate reader (Molecular Devices, Sunnyvale,
CA) based on standard curves of FITC-BSA with excitation
at 488 nm and emission at 520 nm. The auto-fluorescence
background was subtracted with the retina obtained from
the rat without FITC-BSA injection. The retinal permeabil-
ity was calculated and expressed in μl plasma/g dry retina
weight/hr circulation.
Caspase activity
Caspase-3 activity was measured in retinal protein
homogenates using the fluorometric CaspACE assay sys-
tem (Promega). Rats were anesthetized with 100 mg/kg
sodium pentobarbital. Retinas were excised, and placed in
60 μL of cold lysis buffer (25 mM Hepes, pH7.5, 5 mM
MgCl2, 5 mM EDTA, 5 mM DTT, 2 mM PMSF, 10 μg/mL
leupeptin, 1% NP40). The retina was gently sonicated fol-
lowed by 30 minute incubation at 4°C and 20 min cen-
trifugation at 16,000 g at 4°C. Caspase-3 activity was
measured in the supernatants using the fluorometric
CaspACE assay system (Promega) and protein content
was measured by BioRad protein assay. CaspACE assay
was performed according to the manufacturer's protocol
using 50 μg retinal protein and 37°C incubations in a 96-
well plate format.
Microarray analysis
Microarray analysis was performed in the Penn State Col-
lege of Medicine Functional Genomics Core Facility
according to standard procedures.
Total RNA was isolated with Tri-Reagent/BCP (Molecular
Research Center, Cincinnati, OH) following standard
methods [58] and quality and quantity was assessed using
the RNA 6000 Nano LabChip with an Agilent 2100 Expert
Bioanalyzer (Agilent, Palo Alto, CA).
1 μg RNA was transcribed to cRNA following the protocol
of the Codelink iExpress cRNA Prep & Hyb Kit (GE
Healthcare). After second strand synthesis and purifica-
tion of dsDNA using Qiaquick spin columns (Qiagen,
Valencia, CA), T7 reaction buffer, NTPs, 10 mM biotin-11-
UTP, and T7 polymerase were added to the dsDNA and
the reaction was incubated at 37°C for 14 hours. Biotin
labeled cRNA was then purified using RNEasy columns
(Qiagen) followed by quantitation. 10 μg from each sam-
ple was fragmented, denatured and then hybridized to
Codelink rat whole genome microarray slides for 18
hours at 37°C. Slides were then incubated at room tem-
perature with Alexa Fluor 647 labeled steptavidin for 30
minutes followed by washing.
Microarrays were scanned with an Axon 4000B scanner
with GenePix4 v4.0 software at a 5 μm resolution at 635
nm with laser power at 100%, PMT voltage at 600 V, focus
position 0 μm, and lines to average = 1. Images were then
imported into CodeLink Expression Analysis Software
v4.1 (GE Healthcare). Initial quality control (positive and
negative controls), exclusion of manufacturing defects
(MSR spots), background subtraction, and intra-array
normalization was then performed and the results
exported to GeneSpring GX 7.3 (Agilent Technologies).
For data analysis, data was imported into GeneSpring GX
7.3 (Agilent Technologies) and signal values less than
0.01 were set to 0.01, arrays were normalized to the 50th
percentile, and individual genes normalized to the
median. Values were then normalized on a per gene basis
to the control group for each of the two time points (1 or
3 Month). Potential differential expression was deter-
mined with a one-way ANOVA (variances not assumed to
be equal), p < 0.01 and filtered for 1.2 fold and greater dif-
ferences in expression in accordance with standards for
microarray analysis [59,60]. The use of a combination of
statistical and fold-change cutoffs as opposed to tradi-
tional multiple testing corrections (e.g. Bonferroni) pro-
duce gene lists with the lowest rate of type I and type II
errors. 1.2 fold was chosen as the fold change cutoff, as
this magnitude change is at the lower range of changes
confirmable by qPCR. Lastly, probe sequences on the
array were searched against rat genome sequences to elim-
inate any probes for sequences removed by standard
genome processing and annotation. The full complement
of microarray data has been deposited in the NIH/NLM
Gene Expression Omnibus (GEO accession # GSE11733)
[15].
Ontological analysis
Ontological analysis used Gene Ontology (GO) categories
[61]. Differentially expressed processes or functional cate-
gories were determined statistically, similarly to a previ-
ously described approach [16] using GeneSpring GX
software. This analysis determined the number of genes in
a category present on the array and the number of expres-
sion changes that would be part of that category by ran-
dom chance given the number of differentially expressed
genes.
Pathway and network analysis
Ingenuity Pathway Analysis (Ingenuity Systems, Redwood
City CA) was used to create a network from the qPCR con-
firmed gene expression results. Insulin levels, caspase
activity, and vascular permeability data were also
included.
Clustering and statistical analyses
For statistical analysis of qPCR data, standard parametric
t-tests (α < 0.05, two-tailed) were used. Each set (1 and 3
month) of animals was treated independently since the
animals were generated and sacrificed separately. Princi-BMC Medical Genomics 2008, 1:26 http://www.biomedcentral.com/1755-8794/1/26
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pal components analysis clustering was performed using
a mean centered and scaled algorithm (GeneSpring 7.3,
Agilent Technologies).
Quantitative RT-PCR
Quantitative PCR analysis was performed using the 7900
HT Sequence Detection System (Applied Biosystems, Fos-
ter City, CA), 384-well optical plates, and Assay-On-
Demand (Applied Biosystems) gene specific primers and
probes. SDS 2.2.2 software and the 2-ΔΔCtCt  analysis
method [62] were used to quantitate relative amounts of
product using β-actin as an endogenous control. β-actin
levels were determined to be unchanged in an absolute
quantitation experiment (data not shown). For a full list-
ing of primer/probe sets see Table 2, Online Appendix.
For statistical analysis of qPCR data, standard parametric
t-tests (α < 0.05, two-tailed) were used. Each set (1 and 3
month) of animals was treated independently since the
animals were generated and sacrificed separately.
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